JMP Securities maintains PTGX stock with $58 target
JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...
Truist maintains Buy on Protagonist Therapeutics with $60 target
Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...